Pancreatic cancer: Advances and challenges

Stromal and tumor immune microenvironment reprogramming through multifunctional cisplatin-based liposomes boosts the efficacy of anti-PD-1 immunotherapy in pancreatic cancer

“…Pancreatic cancer accounts for almost as many deaths (466 000) as cases (496 000) because of its poor prognosis. 1,2 Due to the fact that approximately 85% of pancreatic cancer patients receive their diagnosis in the late stages of the disease, surgically removing the tumor is extremely difficult. 3 According to the guidelines of the American Cancer Society, the chemotherapeutic agent gemcitabine, alone or in combination with 5-fluorouracil (5-FU), oxaliplatin, irinotecan (CPT-11) and folic acid (FOLFIRINOX), is the standard clinical treatment strategy for pancreatic cancer.…”

A pH-Responsive Nanoplatform Based on Magnetic Mesoporous Silica Nanoparticles for Enhanced Treatment of Pancreatic Cancer

“…Cancer is a major life- and health-threatening disease. Among all cancers, pancreatic cancer is linked to extremely poor prognosis and a <5% survival rate at 5 years. − Although surgical resection is an important means of treatment for pancreatic cancer, more than 80% of the patients are diagnosed in the middle to late stage and lose the opportunity for surgery . The standard treatment for such patients is chemotherapy with gemcitabine hydrochloride .…”

Multifunctional GQDs for receptor targeting, drug delivery, and bioimaging in pancreatic cancer

“…The exact causes of pancreatic cancer are not always fully understood, but several risk factors have been identified such as age, tobacco use, family history and genetics, obesity, chronic pancreatitis, diabetes, diet, alcohol consumption, and occupational exposures. 9,10…”